SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer

Overview of attention for article published in Frontiers in oncology, April 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

twitter: 39 X users

Citations

dimensions_citation: 17 Dimensions

Readers on

mendeley: 37 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 60 X posts from 39 X users, with an upper bound of 104,106 followers.

RT @FrontOncology: 💡💡top Hypothesis and Theory 🥈#2: SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtec…

29 Dec 2021

Reply Repost Favourite

💡💡top Hypothesis and Theory 🥈#2: SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early #BreastCancer 👨‍⚕️👩‍⚕️ Pascual T et al 👉 https://t.co/bz9WpPrVe0 @

29 Dec 2021

Reply Repost Favourite

RT @prat_aleix: @_SOLTI TOTHER3 ongoing trial will shed important light on this topic First results to be presented hopefully @SABCSSanAnt…

06 Jul 2021

Reply Repost Favourite

RT @prat_aleix: @_SOLTI TOTHER3 ongoing trial will shed important light on this topic First results to be presented hopefully @SABCSSanAnt…

06 Jul 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 56 additional X posts.